Daiichi Sankyo (OTCMKTS:DSNKY) Issues Earnings Results

Daiichi Sankyo (OTCMKTS:DSNKY) released its quarterly earnings results on Monday. The company reported $0.15 earnings per share (EPS) for the quarter, Zacks reports. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%. Daiichi Sankyo updated its FY 2026 guidance to 0.910-0.910 EPS.

Daiichi Sankyo Stock Up 3.7%

OTCMKTS:DSNKY traded up $0.61 during midday trading on Monday, reaching $17.12. 255,433 shares of the stock traded hands, compared to its average volume of 445,710. Daiichi Sankyo has a 12-month low of $15.56 and a 12-month high of $28.21. The business has a 50-day moving average of $17.94 and a two-hundred day moving average of $20.47. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. The stock has a market capitalization of $32.43 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 0.85 and a beta of -0.25.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Daiichi Sankyo has a consensus rating of “Buy”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.